Skip to main content

Has asciminib been funded by Pharmac for the treatment of chronic phase Philadelphia chromosome positive (or BCR-ABL1 transcript positive without T315I mutation) chronic myeloid leukaemia in patients previously treated with two or more tyrosine kinase inhibitors, if not, is it under consideration for funding?

Answered Question 18915 (2026)
Question published
Reply lodged
Bookmark

Asked by

Ayesha Verrall

List MP · Labour Party

Question

  • Has asciminib been funded by Pharmac for the treatment of chronic phase Philadelphia chromosome positive (or BCR-ABL1 transcript positive without T315I mutation) chronic myeloid leukaemia in patients previously treated with two or more tyrosine kinase inhibitors, if not, is it under consideration for funding?

Answered by

Hon David Seymour

Member for Epsom · ACT Party · Associate Minister of Health

Answer

I am advised by Pharmac that an application for asciminib for this indication has been received and is currently under assessment. I refer the Member to the following link for more information: https://connect.pharmac.govt.nz/apptracker/s/application-public/a10OZ000000szzN/p002030